AGP Executive Report
Last update: an hour agoMedicinal Cannabis Trials: Avecho’s cannabidiol sleep capsule cleared a pivotal insomnia trial checkpoint, with Australian commercial rights already licensed to a global generics partner. Supply & Exports: BLS Pharmaceuticals says it’s shifting from “making product” to shipping against firm commitments, anchored by an exclusive medicinal cannabis supply deal with a German partner and a second UK production site under construction. Regulatory Pathways: Neurotech International is pursuing the slower, evidence-led route toward registration for a cannabinoid candidate in paediatric neurological conditions, while Little Green Pharma warns Australia’s access pathways are being policed more tightly as dispensing volumes cool. Pain & Opioid-Sparing: Israeli researchers report long-term improvements for treatment-resistant chronic lower back pain patients using prescribed cannabis, including a sharp drop in opioid use. THC Drinks Deadline: New Jersey sets Nov. 13 as the last day liquor stores can sell hemp-derived THC drinks before they move into dispensary-only rules. Public Health Watch: California officials warn about kratom products as newer, more concentrated forms raise safety concerns. Data Security: Spain’s cannabis club software reportedly left Irish passports and IDs exposed online, prompting regulator engagement. Enforcement & Smuggling: Belize’s PM cites record drug seizures and an 80% police conviction rate, while the UK warns young Britons are increasingly detained overseas for cannabis smuggling linked to Thailand.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
